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Molecular Basis and Clinical Overview ofMcLeod Syndrome
ComparedWith Other Neuroacanthocytosis Syndromes
A Review
Eileen Roulis, PhD; Catherine Hyland, PhD; Robert Flower, PhD; Christoph Gassner, PhD;
Hans H. Jung, MD; Beat M. Frey, MD
IMPORTANCE McLeod syndrome, encoded by the gene XK, is a rare and progressive disease
that shares important similarities with Huntington disease but has widely varied neurologic,
neuromuscular, and cardiologic manifestations. Patients with McLeod syndrome have a
distinct hematologic presentation with specific transfusion requirements. Because of its
X-linked location, loss of the XK gene or pathogenic variants in this gene are principally
associated with theMcLeod blood group phenotype in male patients. The clinical
manifestation of McLeod syndrome results from allelic variants of the XK gene or as part of a
contiguous gene deletion syndrome involving XK and adjacent genes, including those for
chronic granulomatous disease, Duchennemuscular dystrophy, and retinitis pigmentosa.
McLeod syndrome typically manifests as neurologic and cardiologic symptoms that evolve in
individuals beginning at approximately 40 years of age.
OBSERVATIONS Diagnosis of McLeod syndrome encompasses a number of specialties,
including neurology and transfusionmedicine. However, information regarding themolecular
basis of the syndrome is incomplete, and clinical information is difficult to find. The
International Society of Blood Transfusion has recently compiled and curated a listing of XK
alleles associated with theMcLeod phenotype. Of note, McLeod syndrome caused by
structural variants as well as those cases diagnosed as part of a contiguous gene deletion
syndromewere previously classified under a singular allele designation.
CONCLUSIONS AND RELEVANCE This review discusses the clinical manifestations and
molecular basis of McLeod syndrome and provides a comprehensive listing of alleles with
involvement in the syndrome published to date. This review highlights the clinical diversity of
McLeod syndrome and discusses the development of molecular tools to elucidate genetic
causes of disease. Amore precise and systematic genetic classification is the first step toward
correlating and understanding the diverse phenotypic manifestations of McLeod syndrome
andmay guide clinical treatment of patients and support for affected and carrier family
members. This review provides a knowledge base for neurologists, hematologists, and clinical
geneticists on this rare and debilitating disease.
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The Story of HughMcLeod and an Interesting
Case of McLeod Syndrome
TheKxantigenand,subsequently, thesyndromeassociatedwith loss
of the antigen were discovered as a result of changes in antigenic-
ity of the Kell blood group.McLeod syndrome (MLS)was first iden-
tified in an otherwise healthy 25-year-old male student at Harvard
dental school,HughMcLeod, throughhis novelKell erythrocyte an-
tigenprofile,whichwasobtainedaspart of anunconsented screen-
ingsurveyundertaken in 1961among incomingstudents.1-3McLeod’s
redblood cellsmanifestedwith evenly depressedKell antigens and
the loss of a public antigen, termed Kx. Initially, the Kx antigenwas
thought to be an antigen of the Kell blood group. The first descrip-
tion of antibody against the Kx antigen (anti-Kx) was published by
Marshet al2 in 1975 in a studyof youngpatientswith chronic granu-
lomatous disease and their relatives. The lack of Kx antigen was
therefore linkedtochronicgranulomatousdisease.However, theab-
sence of chronic granulomatous disease symptoms in McLeod
puzzled researchers because he also lacked Kx antigen on his red
blood cells. We now understand that the reason for the absence of
Kxantigen inMcLeodwas thathis conditionhadageneticbasis that
was considerably different from that of the patients in the survey
byMarsh et al.2
McLeod continued his dental practice, despite progression of
MLS symptoms, to the age of 64 years, and he died when he was
69 years of age.4 The variant responsible for the McLeod pheno-
type was identified as a 13–base pair (bp) deletion at position 938-
951 in theXKgene(OMIM:314850) that resulted inaprematurestop
at amino acid 336.5
Discovery of the XKGene
The Kx antigen is encoded by the XK gene at the p21.1 region of the
X chromosome (accession numbers: NG_007473.2 [genomic], NM
_021083.3 [transcript], LRG_812 [locus reference genomic identi-
fier]). TheXKgenespansa locusof42 501bpwith3exons for a total
coding region of 1335 bp, and the resultingmature protein has 444
aminoacids. Thechromosomal regionassociatedwithMcLeodsyn-
drome was located by comparative probe mapping of 10 samples
frompatientswithMLStoaseriesofspecificallydefinedclonesspan-
ning a region between the 2 loci known to causeDuchennemuscu-
lar dystrophy and chronic granulomatous disease.6 The gene re-
sponsible for theMcLeod phenotypewas defined years later using
radiolabeled cosmid probes, which uncovered a number of large
nucleotide deletions in patientswithMLS. The candidate genewas
identified as XK and displayed a tissue distribution and expression
pattern consistent with MLS.7
McLeodsyndromeandchronicgranulomatousdiseasewere ini-
tially thought to be genetically linked, but we now know that the
genesassociatedwithchronicgranulomatousdisease(CYBB) (OMIM:
300481) andMLS (XK) are separatebut in closeproximity (<50kbp
apart)ontheXchromosome.Thedeletionofall orpartofbothgenes
is oftenassociatedwith a contiguousgenedeletion syndrome,with
larger deletions often involving genes associated with Duchenne
muscular dystrophy (DMD) (OMIM: 300377) and retinitis pigmen-
tosa (RPRG) (OMIM: 300110). This finding indicates that the lack of
KxantigenandMcLeodphenotype intheyoungpatientswithchronic
granulomatous disease in the 1975 study byMarsh et al2 was likely
caused by contiguous gene deletion syndrome rather than specific
geneticvariantsconfinedtotheXK locus,aswasthecaseforMcLeod.
Serologic Presentation of Kx Antigen andMLS
Hematologic findings diagnostic for MLS are distinct and separate
thepresentationofMLS from that of other diseases under theneu-
roacanthocytosis umbrella.8Thepatient shouldpresentwithanab-
senceofKx antigen and reducedexpressionofKell bloodgroupan-
tigensdemonstratedusingapanelofhumananti-Kxandmonoclonal
anti-Kell antibodies. This initial presentation facilitates a diagnostic
algorithm for confirmatory testing ofMLS. Thepresenceof theKEL
gene (OMIM:613883) shouldbeconfirmedusingpolymerase chain
reaction or othermolecularmethods to differentiate from theKell-
null phenotype.9 Thepatient should be assessed for alloantibodies
against the high-frequency antigen Kx, the high-frequency Kell an-
tigen Km (also known as KEL20), and the presence of a compen-
sated hemolytic state. The level of biochemicalmarkers associated
with hemolysis, such as lactate dehydrogenase and haptoglobin,
should be determined, and serum creatine kinase levels, which are
usually elevated inpatientswithMLSwith concentrations reaching
4000U/L (to convert tomicrokatals per liter, multiply by 0.0167),
should alsobedetermined. Thepresenceof redbloodcell acantho-
cytes should be confirmed using phase-contrast microscopy.8
Neuroacanthocytosis andMLS
McLeod syndrome is part of the spectrum of neuroacanthocytosis
syndromes,whicharedefinedasprogressiveneurodegenerativedis-
eases that affect mainly basal ganglia, including nucleus caudatus
and putamen, in association with red blood cell anomalies, such as
acanthocytosis.8-12 Major representatives of neuroacanthocytosis
sydromeswithvastlyoverlappingclinical featuresare theautosomal-
recessive choreoacanthocytosis (ChAc) and the X-linked MLS. Al-
though panthothenate-kinase–associated neurodegeneration and
Huntingtondisease–likedisordermay rarely be associatedwith red
blood cell acanthocytosis, these syndromes markedly differ from
ChAc and MLS with respect to age of onset and mode of inheri-
tance. Clinical features of the neuroacanthocytosis syndromes are
outlined in the Table.
Autosomal-recessive choreoacanthocytosis and MLS share
many common phenotypic features, such as choreatic movement
disorder, cognitive impairment and associated psychiatric disor-
ders, seizures, and neuromuscular involvement with elevated cre-
atine kinase levels, myopathy, and peripheral neuropathy associ-
atedwithdiminishedor abolisheddeep-tendon reflexes.10,13 These
neuromuscular manifestations may widely differ in severity, rang-
ing from isolatedelevationof creatinekinase levels todisablingmus-
cularweaknessandatrophy.Becauseserumtransaminase levelsmay
also be elevated in patients with MLS,14 patients have been misdi-
agnosedwithhepatopathy.However, somepatientswithMLShave
hepatosplenomegaly,mostprobably resulting froman increasedred
blood cell turnover caused by elevated red blood cell clearance in
the context of the acanthocytic changes.5,15
Several neurologic manifestations in patients with ChAc, such
as tongue and lip biting, tongue protrusion dystonia, head drops,
parkinsonism, and truncal dystonia, were formerly believed to be
specific for this disorder. However, recent reports describe these
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manifestations inpatientswithMLS,whichsuggestsawidely shared
clinical spectrumbetweenChAcandMLS.16,17Themajordistinguish-
ing clinical features of MLS are mode of inheritance, red blood cell
immunophenotype,andcardiologic involvement—mainlydilatedcar-
diomyopathy and arrhythmias.
Phenotypic Variability
McLeod syndromemay exhibit a considerable phenotypic variabil-
ity, evenwithin the same family,with regard to the ageat onset, the
presentingsymptoms,thedevelopmentofadditionalsymptoms,and
thecourseof thedisease.18 InaseriesofpatientswithMLS,3hadMLS
detectedasa resultofdonatingblood,3presentedwithvariablepsy-
chiatricdisorders,2 reportedmuscularweaknessandatrophyorepi-
leptic seizures, andonly 1 hadachoreaticmovementdisorder at the
disease onset.4
Although the rarity of the disorder does not allow a conclusive
genotype-phenotype correlation, available data suggest that mis-
sensemutations in theXKgene tendto lead to lesspronouncedneu-
rologicandneuromuscular symptomswitha lateronset thanXKvari-
ants that cause truncation or nonexpression of theXKprotein.19,20
This would be consistent with a residual physiologic activity in fe-
male carriers of XKmissense mutations.14,21 However, all available
clinical reports are consistentwith a full penetrance ofMLS inmen,
albeit possibly at an older age and possibly with nondisabling neu-
rologic or neuromuscular symptoms. These considerations are im-
portant in the context of genetic counseling of patients with MLS
and family members at risk of disease.
Clinical Diagnosis of MLS
ThevariablepresentationofXp21.1.mutations18,19,22,23 togetherwith
lateonsetof clinical symptomsmake thediagnosis ofMLSchalleng-
ing. Diagnosis is almost exclusively restricted tomale,middle-aged
patients who exhibit a progressive chorea syndrome with the ex-
clusionofotherpathologies suchasHuntingtondisease,Wilsondis-
ease, ChAc, and c9orf72-related disorders.8,24,25 Neurologic pre-
sentation of symptoms is highly variable, although choreatic
movement disorder; dystonia; cognitive impairment with prema-
ture dementia; psychiatric disorders including depression, bipolar
disorder, and obsessive-compulsive disorder; and personality
changes are common.16,17,26 Areflexia or hyporeflexia are charac-
teristic as are elevated creatine kinase levels and red blood cell ab-
normalities ranging from overt acanthocytosis to elevated rates of
hyperchromic redbloodcells inautomatedhematologicanalysis. Se-
rologic test results that indicateanabsenceof theKxantigenareused
to confirm diagnosis. Among blood donors with MLS, the absence
of theKxantigenmayberecognizedmanyyearsbeforeclinicalmani-
festation of symptoms and may even lead to an early diagnosis of
MLS in asymptomaticblooddonors.3,19 This is important tonote for
hematologists because this finding implies the probable develop-
mentofneurologic and/orneuromuscular symptoms later in life and
the necessity for neurogenetic counseling of these blood donors.
In addition tomutations at the XK locus, large X-chromosomal
deletions involvingXK and its neighboring locimay lead to contigu-
Table. Clinical Presentation andMolecular Basis of Neuroacanthocytosis Syndromes
Characteristic
Chorea-
Acanthocytosis McLeod Syndrome
Huntington
Disease-Like 2
Pantothenate
Kinase-Associated
Neurodegeneration
Gene VPS13A XK JPH3 PANK2
Protein Chorein XK Junctophilin-3 Pantothenate kinase-2
Inheritance Autosomal recessive X-linked Autosomal
dominant
Autosomal recessive
Acanthocytes +++ +++ +/− +/−
Cellular
compartment
Cytoplasm Membrane Cytoplasm Mitochondria
Membrane proteins
affected
Band3/adducin, actin
junctional complex
Band3/4.1R complex,
actin junctional
complex
None None
Red blood cell
phenotype
Unaffected Weak Kell antigens, Kx
antigen absent
Unaffected Unaffected
Serum creatine
kinase level, U/L
300-3000 300-3000 Normal Normal
Neuroimaging Striatal atrophy Striatal atrophy Striatal and
cortical atrophy
“Eye of the tiger” sign in the
globus pallidus
Age of onset, y 20-30 25-60 20-40 Childhood
Chorea +++ +++ +++ −
Other movement
disorders
Feeding and gait
dystonia, tongue and
lip biting,
parkinsonism
Vocalizations,
parkinsonism
Dystonia,
parkinsonism
Dystonia, parkinsonism,
spasticity
Seizures Generalized,
partial-complex
Generalized None None
Neuromuscular
manifestations
Areflexia, weakness,
atrophy
Areflexia, weakness,
atrophy
None None
Cardiac
manifestations
None Atrial fibrilliation,
malignant arythmias,
dilative
cardiomyopathy
None None
Abbreviations: −, absent; +, present;
+++, maximum presence.
SI conversion: To convert serum
creatine kinase to microkatals per
liter, multiply by 0.0167.
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ous gene deletion syndrome,27 the clinical manifestation of which
is dictatedbydeletedgenesbothupstreamanddownstreamofXK,
such asDMD,CYBB, andRPRG. Patientsmay experienceDuchenne
musculardystrophy, chronicgranulomatousdisease,or retinitis pig-
mentosa, respectively.Other coaffectedgenesatXp21.1withpoorly
defined biologic functions, such asMRXS17, BCMP1,MAGEB16, and
PRRG1,maymodify the clinical presentationof contiguousgenede-
letion syndrome. If several genes are affected, disease symptoms
may develop sequentially over time, ultimately leading to a dismal
outcome,28 although theclinical presentationanddiagnosis of con-
tiguousgenedeletionsyndrometypicallyoccursatanearlyage.28,29
Treatment options for MLS and contiguous gene deletion syn-
drome are limited to symptomatic care to prevent secondary com-
plications, such as amelioration of dystonia and choreatic move-
ment disorder,30 treatment of muscular degeneration,31,32 and
treatment of infectious complications in chronic granulomatous
disease.33
WomenwithManifestations ofMLS
As anX-linked neuroacanthocytosis syndrome,MLS is overwhelm-
inglyconfinedtomalepatients. Lyonization (orX-inactivation)of the
defective gene results in a normal phenotype or, rarely, weakened
clinical presentation in women. It is possible that severe MLS in
women could occur as the result of a compoundheterozygosity, al-
though to our knowledge, this is yet to be reported.34
Of interest, in the only case of awomanwith confirmed severe
MLS toourknowledge, theprobandwasheterozygous for a 1-bpde-
letion in exon 2 in the XK gene (268delT terminating at AA129). It
was shown that severely skewed lyonization resulted in inactiva-
tionof thenormalXKgene in all tissues, including thebrain. Thepa-
tient developed seizures at 50 years of age, with gradual progres-
sion of neurologic symptoms including chorea and cognitive
impairmentbeforeher death at60years of age.14,21 Bothof thepa-
tient’s sons hadMLS, with neurohematologic symptomsmanifest-
ing from their early to mid-20s before their deaths at the age of 31
years. The patient’s sister and niece each exhibitedmild neurologic
symptoms (lower limb chorea and ankle areflexia) with variable
presentation of Kell antigens, whereas the skew of lyonization
ranged from slightly skewed in the sister to completely normal in
the niece. Age-related skew of lyonization has been reported
in female patients who present with progressive X-linked
disorders,35,36 which could explain the difference in skew between
affectedwomen. All familymembers with the variant, including het-
erozygotes, had hematologic profiles—acanthocytosis and elevated
creatine kinase levels—that were consistent with MLS to varying
degrees.
Biochemistry and Cell Biology of XK
In the red blood cell membrane, XK is a 10-transmembrane protein
that forms a heterodimer with the Kell glycoprotein via the disul-
fide bond at XKCys347-KellCys72, as shown in Figure 1A. The XK-Kell
dimer is part of the membrane multiprotein complex subunit 4.1,
which also containsBand3glycoprotein, glycophorinC,Rhprotein/
Rh-associated glycoprotein, and Duffy protein38 (Figure 1B). The
membranemultiproteincomplexcytoskeletonnetworkcontrols the
bloodcell discocyteshapeanddeterminescell deformability, among
other properties.39,40 Similar to other multipass-membrane trans-
port proteins, XKmay be an important gate keeper for transmem-
brane exchange of electrolytes and nutrients.41 It has been shown
that absence of the XK-Kell membrane complex alters erythrocyte
homeostasis of divalent cations,42,43 which may explain prema-
ture hemolysis of red blood cells in individuals withMLS by impair-
ment of Ca2+-activated K+ channels (Gardos channels).44 Lipid im-
balance between the inner and outer red blood cell membrane
leaflets leads toacanothcyticdeformationof theredbloodcellmem-
brane. The absence of XK protein in themembrane leads to dimin-
ished levels of phosphatidylserine in the inner leaflet,which causes
shrinkage of the membrane, interfering with transmembrane me-
tabolite transport.45,46
In many nonerythroid tissues, the XK protein and Kell protein
are expressed independently from each other, and in most tissue,
including thebrainandotherneuronal tissue,onlyXK is translated.47
TheXKproteinhasbeen shown tohaveapivotal role inorganogen-
esis, cellular structure, and subcellular electrolyte and nutrient
exchange, accounting for themultisystemic deficiency phenotype,
which includes neurologic, neuropsychiatric, neuromuscular, and
cardiologicmanifestations.4,5,48 As amatter of course, all manifes-
tations attributable to XK alone may be drawn only from observa-
tions in (andexperiments involving) individualswithmutations lim-
ited to the XK locus who do not exhibit a contiguous gene deletion
syndrome.
Genetic Classification of XKAlleles
and theMolecular Basis of MLS
The International SocietyofBloodTransfusion (ISBT) recognizes the
XK protein and Kx antigen as an independent blood group system,
defined as number019 of the currently recognized 36blood group
systems. At present, the data described in the XK allele database
comprise themost complete repository of variants with an associ-
atedMcLeod phenotype.
The Kx antigen, encoded by the native XK protein, is desig-
natedasthereferencealleledefinedasXK*01.Nootherantigenshave
been defined in this system. The XK gene shows 8.2 variants per
kilobase coding sequence, thereby ranking as one of themost con-
served blood group genes, second only to Chido/Rodgers, en-
coded by C4A and C4B, with 5.5 and 4.4 variants per kilobase,
respectively.49 In addition to the variants described in the ISBT
database, an additional 66 variants coding for changes in XK, in-
cluding 1nonsensevariant,havebeenreported in thedbSNP(single-
nucleotide polymorphismdatabase). It is unknownwhether any of
these variants have an associatedMLS phenotype.
Until this review, 29 variant alleles associated with the McLeod
phenotype were listed in the ISBT database and defined as XK*N
from01 to 29, withN indicating null. Review of the literature shows
that this is now an underestimate and that at least 56 variant XK
alleles have been described in conjunction with neurogenic or
hematologic XK phenotypes. The variants are subdivided into 2
groups: variants residing within XK (39 alleles) or whole gene dele-
tions, including contiguous gene deletions involving the XK gene
(17 alleles). Consequently, and in conjunctionwith the ISBTworking
party, we have compiled a comprehensive listing of all described
MLS and neurogenically associated variants involving the XK
gene.50 This listing provides neurologists, clinical geneticists, and
transfusion specialists with a reference to further investigate the
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molecular basis of MLS and report findings of novel alleles or dele-
tions in individuals presenting with a McLeod phenotype.
Review of the XK*NAllelic Variant Group
Themajority ofXK*N alleles consist of variants in 1 of the 3 exons or
splice site loci of the XK gene. A summary of the XK allele variants
derivedfromthe ISBTdatabase ispresented ineTable 1 in theSupple-
ment. The location of single-nucleotide variants and indels associ-
ated with theMLS phenotype are depicted in Figure 1C.
Manyof thesevariants are single-nucleotidepolymorphismsor
small deletions that result in aminoacid changesor frameshifts and
early termination of the XK protein. Only 2 single-nucleotide inser-
tionswith aMcLeodphenotype association are noted.51-53 Nucleo-
tide variants resulting in amino acid substitutions presumably dis-
rupt transmembrane helices and change conformation for the
mature protein within the cell membrane. A splice sitemutation 13
bpdownstreamof theexon3acceptor sitehasbeenassociatedwith
psychiatric pathology (schizophrenia) and acanthocytosis in pa-
tients but was not described as presenting with a McLeod
phenotype.54Only3of theXKvariantswithanMLSassociationhave
been listed in the dbSNP database (rs numbers 28933690,
104894954, and 104894953); 5 variants are listed with a ClinVar
accession, whereas 2 splice site variants have listed ExAC/
GnomAD population-level frequencies. Most alleles are reported
from a single patient or family grouping. However, 5 alleles have
been reported in more than 1 study—for instance, the R133X vari-
Figure 1. XK-Kell Complex and Amino Acid Variation in theMcLeod Phenotype
4.1R multiprotein complexBXK protein conformationA
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XK is a 444–amino acid, 10-transmembrane protein that forms a dimer with the
Kell protein in the 4.1R complex of the red blood cell membranemultiprotein
complex. A, Ten-transmembrane conformation of the XK protein, with its
disulphide linkage at XKCys347-KellCys72 in red. B, Main components of the
4.1R-dependent multiprotein complex in the red blood cell membrane. The 4.1R
protein, which anchors the red cell membrane components, is depicted with its
3-lobe structure: A, B, and C. Defects in components of the 4.1R complex can
lead to instability and deformity of the red blood cell membrane, such as the
presentation of acanthocytosis seen in McLeod syndrome (MLS). C, The XK
protein, showing the arrangement of exons, locations of transmembrane
segments, and locations of amino acid changes associated with theMLS
phenotype. The XK protein variant map was generated with Geneious 11.0.5
(Biomatters Limited) using human genome release Hg19 p13.7.37
COOH indicates carboxyl group; GPC, glycophorin C protein.
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ant has been reported in 3 separate studies from apparently unre-
lated kindreds5,55,56 (these cases are outlined in eTable 2 in the
Supplement).
Review of the XK*N.01 SeriesWith Contiguous
Gene Deletions
Todate, 17wholegeneor contiguousgenedeletions that includeXK
have been published (these are outlined in eTable 3 in the Supple-
ment). Because of themolecular technologies available at the time
thatmanyof theolderdeletionsweredefined,breakpoints for these
deletions are not preciselymapped. Given the rarity of whole gene
deletionsandcontiguousgenedeletions involvingXK, theprobabil-
ity that the same deletion will be tabulated more than once is un-
likely except in cases in which descent can be confirmed from fa-
milial studies. The suballeles are listed on the basis of the accuracy
of locus and nucleotide discrimination: those that were character-
izedusingoldermethods, suchasmicroscopicexaminationorkaryo-
typing and probe deletion analyses,57,58 and those for which de-
scriptions of deletions are determined with breakpoints to the
nucleotide level. Figure 2 illustrates the range of the deletions as-
sociatedwithMLSandcontiguousgenedeletion syndromes for the
6 cases in which exact breakpoints are defined.
Wholegenomesequencingnowallowsresearchers tomoreeas-
ilydeterminethenucleotidebreakpoints involved incontiguousgene
deletion syndrome and MLS. In addition, polymerase chain reac-
tion andSanger sequencing targeting splice site andexonic regions
or stepwisepartitionedpolymerasechain reactionanalysisofXKand
flanking regionsare still used for thediscoveryofmutations respon-
sible for theMcLeod blood group phenotype.27,59 In the case of XK
deletions, the stepwise partitioning method can be used to deter-
mine exact nucleotide breakpoints without the requirement for
whole genome sequencing.27 With the introduction of third-
Figure 2. Scale and Variability of Deletions in Contiguous Gene Deletion SyndromesWithMcLeod Syndrome (MLS) Phenotype
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37 407 788 38 122 52936 407 78835 407 78834 407 78833 407 78832 407 789
35 839 433 36 089 432 36 339 432 36 589 432 36 839 432 37 089 432 37 339 432 37 589 432
37 872 103 37 965 79737 772 10337 672 10337 572 10337 472  10337 372 104
31 683 512 32 683 511 33 683 511 34 683 511 35 683 511 36 683 511 37 789 441
37 508 31837 408 31837 308 31837 208 31837 108 31837 008 31836 908 31836 808 319
37 497 065 37 517 064 37 517 064 37 557 064 37 577 064 37 597 064 37 617 064 37 648 529
Six contiguous gene deletions in the Xp21.1 locus with clearly defined nucleotide
breakpoints are shown. The deletions involve XK, with clinical presentation of
MLS. The deletions span from0.15 megabase pairs (Mbp) to 5.71 Mbp and
involve 3 tomore than 15 genes. The scale depicts the size and number of
nucleotides in the X-chromosome. The genemaps were generated with
Geneious 11.0.5 (Biomatters Limited) using human genome release Hg19 p13.7.37
L, LANCL3; and P, PRRG1.
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generation sequencing technologies, suchas theBioRadSMRTand
Oxford Nanopore ION systems, the detection and analysis of very
large-scaledeletionswill becomeeasier and the characterizationof
breakpoints easier to define. A more precise and systematic ge-
netic classification is the first step toward correlating and under-
standing the diverse phenotypic clinical manifestations of MLS to
guidemanagement strategies.
Treatment and Future Directions
The importance of early and correct diagnosis, along with the role
that hematology laboratories can play in this early detection, has
beenreviewedelsewhere.9Currently, treatmentofpatientswithMLS
andassociatedcontiguousgenedeletionsyndromes involvesmoni-
toringandameliorationofsymptoms.Dopamineantagonistsandthe
dopaminedepletorydrug tetrabenazinearegiven toameliorate the
choreatic movement disorders, whereas treatment of psychiatric
problems,cardiacabnormalities,andseizures isbasedonclinical find-
ings andwhether contiguous geneswith additional clinical presen-
tations are involved. Regardless, long-term and continuous multi-
disciplinary support is needed for affected individuals and their
families, includinggenetic counselingof affectedandpotentially af-
fectedmale relatives.
The rarebloodgroupphenotypecharacteristic forpatientswith
MLS, in lacking theKxantigen,presents challenges.Anypatient car-
rying theMcLeod immunophenotypebecauseofeitherMLSor con-
tiguous gene deletion syndrome and requiring transfusion support
requires the care and support of specialist transfusion institutions.
In suchcases, the immunohematologic andmolecularworkup isde-
manding, and the rarity of compatible blood products often re-
quires interinstitutional or international collaboration for provision
of compatible units.8 In any case of transfusion requirement, Kx+
transfusions should be avoided for both male and female patients
carryingaMcLeodphenotype.Autologousbankeddonationsare the
most suitable transfusion practice if feasible.
Treatment options using allogeneic stem cell transplant thera-
pies have been reported with some success.60 A young man with
MLS and chronic granulomatous disease who had developed anti-
bodies toKxandKell aftera redbloodcell transfusion receivedasuc-
cessful allogeneic stem cell transplant at 14 years of age, with ob-
served complete chimerism and engraftment after 10-month
follow-up.61,62 Unfortunately, there is no guarantee that a success-
ful transplant will prevent late onset of neurologic and neuromus-
cular symptoms or cardiac complications associatedwith inherited
Xp21.1 defects.
Recent studies have demonstrated promising results with the
use of nonhomologous end-joining recombination using RNA-
guided CRISPR/Cas9 nucleases in repairing short indel and frame-
shiftvariations inthechronicgranulomatousdiseasegeneCYBB,with
less success in repairing single-nucleotide variants leading to non-
sense andmissensemutations. Although the technology is still in its
infancy, these therapiesmay be directly translatable to othermono-
genic hematopoetic blood disorders, such as MLS.63,64 In addition,
the use of targeted insertion of therapeutic transgenes into defined
viral integrationsiteswill allowforalterationof thepatient’sownstem
cells for transplantation.65 Of note, the morphologically, function-
ally,andstructurallyalteredredbloodcells inXKmutationcarriersmay
provideaneasilyaccessiblecellularsubstratetodeterminethepatho-
biologic features of Xp21.1 mutations and to discover new potential
therapeutic strategies for improvement of multisystem manifesta-
tions ofMLS.66
Conclusions
McLeodsyndrome isaprogressive,debilitatingX-linkedneurohema-
tologic disorder that is caused by variation in the XK gene, resulting
in truncationof thematureXKproteinorchanges in transmembrane
conformationand structurewithin the redbloodcellmembraneand
other tissues. McLeod syndrome can also present as part of a con-
tiguousgenedeletionsyndromecausedbyawholeorpartialgenede-
letion, includingdeletionof adjacent genes suchasCYBB,DMD,and
RPGR. It can occur in individuals 20 years of age or older, whereas
neurologic, neuromuscular, and cardiologic manifestations vary
widely and occur late in a patient’s life. Information on themolecu-
lar basis of MLS and associated gene deletion syndromes has pre-
viouslybeendiffuseandwidelydistributed.Wecollectedandelabo-
rated on themolecular basis ofMLS to provide a reference base for
clinicians.
ARTICLE INFORMATION
Accepted for Publication: June 8, 2018.
Published Online: August 20, 2018.
doi:10.1001/jamaneurol.2018.2166
Author Contributions:Drs Frey and Roulis had full
access to all the data in the study and take
responsibility for the integrity of the data and the
accuracy of the data analysis.
Concept and design: All authors.
Acquisition, analysis, or interpretation of data:
Roulis, Hyland, Jung, Frey.
Drafting of the manuscript: Roulis, Hyland, Flower,
Frey.
Critical revision of the manuscript for important
intellectual content: Roulis, Hyland, Gassner, Jung,
Frey.
Obtained funding: Flower.
Administrative, technical, or material support:
Roulis.
Supervision:Hyland, Flower, Gassner.
Conflict of Interest Disclosures:Drs Hyland and
Gassner are members and cochairpersons of the
International Society of Blood TransfusionWorking
Party “Red Cell Immunogenetics and Blood Group
Terminology.”
Funding/Support: The Australian government
funds the Australian Red Cross Blood Service for the
provision of blood, blood products, and services to
the Australian community.
Role of the Funder/Sponsor: The funder had no
role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of themanuscript; and decision to submit
themanuscript for publication.
Additional Contributions:We thank Dr Jill Storry,
PhD (Division of Hematology and Transfusion
Medicine, Lund University, Lund, Sweden), for
permission to include the updated XK allele tables.
Dr Storry was not compensated.
REFERENCES
1. MarshWL. The Kell blood group, Kx antigen, and
chronic granulomatous disease.Mayo Clin Proc.
1977;52(3):150-152.
2. MarshWL, Oyen R, Nichols ME, Allen FH Jr.
Chronic granulomatous disease and the Kell blood
groups. Br J Haematol. 1975;29(2):247-262. doi:10
.1111/j.1365-2141.1975.tb01819.x
3. Allen FH Jr, Krabbe SM, Corcoran PA. A new
phenotype (McLeod) in the Kell blood-group
system. Vox Sang. 1961;6:555-560. doi:10.1111/j
.1423-0410.1961.tb03203.x
4. Hewer E, Danek A, Schoser BG, et al. McLeod
myopathy revisited: more neurogenic and less
benign. Brain. 2007;130(Pt 12):3285-3296. doi:10
.1093/brain/awm269
Molecular Basis and Clinical Overview of McLeod Syndrome ComparedWith Other Neuroacanthocytosis Syndromes Review Clinical Review & Education
jamaneurology.com (Reprinted) JAMANeurology Published online August 20, 2018 E7
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 11/11/2018
5. Danek A, Rubio JP, Rampoldi L, et al. McLeod
neuroacanthocytosis: genotype and phenotype.
Ann Neurol. 2001;50(6):755-764. doi:10.1002/ana
.10035
6. Bertelson CJ, Pogo AO, Chaudhuri A, et al.
Localization of theMcLeod locus (XK) within Xp21
by deletion analysis. Am J HumGenet. 1988;42(5):
703-711.
7. HoM, Chelly J, Carter N, Danek A, Crocker P,
Monaco AP. Isolation of the gene for McLeod
syndrome that encodes a novel membrane
transport protein. Cell. 1994;77(6):869-880. doi:10
.1016/0092-8674(94)90136-8
8. Jung HH, Danek A, Frey BM. McLeod syndrome:
a neurohaematological disorder. Vox Sang. 2007;93
(2):112-121. doi:10.1111/j.1423-0410.2007.00949.x
9. Frey BM, Gassner C, Jung HH.
Neurodegeneration in the elderly—when the blood
typematters: an overview of theMcLeod syndrome
with focus on hematological features. Transfus
Apher Sci. 2015;52(3):277-284. doi:10.1016/j.transci
.2015.04.007
10. Walker RH, Jung HH, Danek A.
Neuroacanthocytosis. In: Weiner W, Tolosa E, eds.
Hyperkinetic Movement Disorders. Edinburgh:
Elsevier;2011:141-151. Handbook of Clinical Neurology;
vol 100.
11. Valko PO, Hänggi J, Meyer M, Jung HH.
Evolution of striatal degeneration in McLeod
syndrome. Eur J Neurol. 2010;17(4):612-618. doi:10
.1111/j.1468-1331.2009.02872.x
12. Walker RH, Jung HH, Dobson-Stone C, et al.
Neurologic phenotypes associated with
acanthocytosis. Neurology. 2007;68(2):92-98. doi:
10.1212/01.wnl.0000250356.78092.cc
13. Jung HH, Danek A, Walker RH.
Neuroacanthocytosis syndromes.Orphanet J Rare
Dis. 2011;6:68. doi:10.1186/1750-1172-6-68
14. Hardie RJ, Pullon HW, Harding AE, et al.
Neuroacanthocytosis: a clinical, haematological and
pathological study of 19 cases. Brain. 1991;114(Pt
1A):13-49.
15. Walker RH, Danek A, Jung HH, Davey R, Reid M.
McLeod syndrome presenting with hepatic disease.
(Poster Session 1—P20). Poster presented at: Ninth
International Congress of Parkinson’s Disease and
Movement Disorders; March 6, 2005; NewOrleans,
LA.
16. ChauveauM, Damon-Perriere N, Latxague C,
et al. Head drops are also observed in McLeod
syndrome.Mov Disord. 2011;26(8):1562-1563. doi:
10.1002/mds.23605
17. Gantenbein AR, Damon-Perrière N, Bohlender
JE, et al. Feeding dystonia in McLeod syndrome.
Mov Disord. 2011;26(11):2123-2126. doi:10.1002
/mds.23843
18. MirandaM, Castiglioni C, Frey BM, Hergersberg
M, Danek A, Jung HH. Phenotypic variability of a
distinct deletion in McLeod syndrome.Mov Disord.
2007;22(9):1358-1361. doi:10.1002/mds.21536
19. Jung HH, Hergersberg M, Vogt M, et al. McLeod
phenotype associated with a XKmissensemutation
without hematologic, neuromuscular, or cerebral
involvement. Transfusion. 2003;43(7):928-938.
doi:10.1046/j.1537-2995.2003.t01-1-00434.x
20. Walker RH, Danek A, Uttner I, Offner R, Reid M,
Lee S. McLeod phenotype without theMcLeod
syndrome. Transfusion. 2007;47(2):299-305. doi:
10.1111/j.1537-2995.2007.01106.x
21. Danek A, NeumannM, Brin MF, SymmansWA,
Hays AP. Cerebral involvement in McLeod
syndrome: the first autopsy revisited. In: Walker
RH, Saiki S, Danek A, eds.Neuroacanthocytosis
Syndromes II. Berlin: Springer; 2008:205-215. doi:
10.1007/978-3-540-71693-8_17
22. Walker RH, Jung HH, Tison F, Lee S, Danek A.
Phenotypic variation among brothers with the
McLeod neuroacanthocytosis syndrome.MovDisord.
2007;22(2):244-248. doi:10.1002/mds.21224
23. Aasly J, Skandsen T, RøM. Neuroacanthocy-
tosis: the variability of presenting symptoms in two
siblings. Acta Neurol Scand. 1999;100(5):322-325.
doi:10.1111/j.1600-0404.1999.tb00404.x
24. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky
ML. Wilson’s disease. Lancet. 2007;369(9559):
397-408. doi:10.1016/S0140-6736(07)60196-2
25. Liu Y, Yu JT, Zong Y, Zhou J, Tan L. C9ORF72
mutations in neurodegenerative diseases.Mol
Neurobiol. 2014;49(1):386-398. doi:10.1007
/s12035-013-8528-1
26. Danek A, Bader B, Walker RH. Antisocial
behaviour and neuroacanthocytosis. Int J Clin Pract.
2007;61(8):1419. doi:10.1111/j.1742-1241.2007.01371.x
27. Gassner C, Brönnimann C, Merki Y, et al.
Stepwise partitioning of Xp21: a profiling method
for XK deletions causative of theMcLeod
syndrome. Transfusion. 2017;57(9):2125-2135. doi:
10.1111/trf.14172
28. Francke U, Ochs HD, deMartinville B, et al.
Minor Xp21 chromosome deletion in a male
associated with expression of Duchennemuscular
dystrophy, chronic granulomatous disease, retinitis
pigmentosa, andMcLeod syndrome. Am J Hum
Genet. 1985;37(2):250-267.
29. Peng J, Redman CM,Wu X, et al. Insights into
extensive deletions around the XK locus associated
with McLeod phenotype and characterization of
two novel cases. Gene. 2007;392(1-2):142-150.
doi:10.1016/j.gene.2006.11.023
30. Walker RH. Management of neuroacanthocy-
tosis syndromes. Tremor Other Hyperkinet Mov (N Y).
2015;5:346.
31. Bushby K, Finkel R, Birnkrant DJ, et al; DMD
Care ConsiderationsWorking Group. Diagnosis and
management of Duchennemuscular dystrophy,
part 1: diagnosis, and pharmacological and
psychosocial management. Lancet Neurol. 2010;9
(1):77-93. doi:10.1016/S1474-4422(09)70271-6
32. Bushby K, Finkel R, Birnkrant DJ, et al; DMD
Care ConsiderationsWorking Group. Diagnosis and
management of Duchennemuscular dystrophy,
part 2: implementation of multidisciplinary care.
Lancet Neurol. 2010;9(2):177-189. doi:10.1016
/S1474-4422(09)70272-8
33. Chronic granulomatous disease: treatment and
prognosis. UpToDate; 2018. https://www.uptodate
.com/contents/chronic-granulomatous-disease-
treatment-and-prognosis. Accessed November 15,
2017.
34. Reid ME, Lomas-Francis C, OlssonML. XK–Kx
blood group system. In: Reid ME, Lomas-Francis C,
OlssonML, eds. The Blood Group Antigen FactsBook.
3rd ed. Boston: Academic Press; 2012:499-504. doi:
10.1016/B978-0-12-415849-8.00021-1
35. Busque L, Paquette Y, Provost S, et al. Skewing
of X-inactivation ratios in blood cells of aging
women is confirmed by independent
methodologies. Blood. 2009;113(15):3472-3474.
doi:10.1182/blood-2008-12-195677
36. Bicocchi MP, Migeon BR, PasinoM, et al.
Familial nonrandom inactivation linked to the X
inactivation centre in heterozygotes manifesting
haemophilia A. Eur J HumGenet. 2005;13(5):
635-640. doi:10.1038/sj.ejhg.5201386
37. Kearse M, Moir R, Wilson A, et al. Geneious
Basic: an integrated and extendable desktop
software platform for the organization and analysis
of sequence data. Bioinformatics. 2012;28(12):
1647-1649. doi:10.1093/bioinformatics/bts199
38. Lux SE IV. Anatomy of the red cell membrane
skeleton: unanswered questions. Blood. 2016;127
(2):187-199. doi:10.1182/blood-2014-12-512772
39. Cartron JP, Bailly P, Le Van Kim C, et al. Insights
into the structure and function of membrane
polypeptides carrying blood group antigens. Vox
Sang. 1998;74(suppl 2):29-64. doi:10.1111/j.1423-0410
.1998.tb05397.x
40. Olivieri O, De Franceschi L, Bordin L, et al.
Increasedmembrane protein phosphorylation and
anion transport activity in chorea-acanthocytosis.
Haematologica. 1997;82(6):648-653.
41. Uniprot. P51811. (XK_HUMAN). 2017;
http://www.uniprot.org/uniprot/P51811. Accessed
July 10, 2017.
42. Rivera A, Kam SY, HoM, Romero JR, Lee S.
Ablation of the Kell/Xk complex alters erythrocyte
divalent cation homeostasis. Blood Cells Mol Dis.
2013;50(2):80-85. doi:10.1016/j.bcmd.2012.10.002
43. Romero JR, Markovic A, Schorer G, et al.
Alterations in magnesium and potassium but not
sodium transporters characterize McLeod
syndrome erythrocytes. Paper presented at: Third
Joint Symposium on Neuroacanthocytosis and
Neurodegeneration with Brain Iron Accumulation:
From Benchside to Bedside; November 1, 2014;
Stresa, Italy.
44. De Franceschi L, Rivera A, FlemingMD, et al.
Evidence for a protective role of the Gardos channel
against hemolysis in murine spherocytosis. Blood.
2005;106(4):1454-1459. doi:10.1182
/blood-2005-01-0368
45. Redman CM, Huima T, Robbins E, Lee S, Marsh
WL. Effect of phosphatidylserine on the shape of
McLeod red cell acanthocytes. Blood. 1989;74(5):
1826-1835.
46. Lin S, Yang E, Huestis WH. Relationship of
phospholipid distribution to shape change in
Ca(2+)-crenated and recovered human
erythrocytes. Biochemistry. 1994;33(23):7337-7344.
doi:10.1021/bi00189a039
47. Clapéron A, Hattab C, Armand V, Trottier S,
Bertrand O, Ouimet T. The Kell and XK proteins of
the Kell blood group are not co-expressed in the
central nervous system. Brain Res. 2007;1147:12-24.
doi:10.1016/j.brainres.2007.01.106
48. Danek A, Tison F, Rubio J, Oechsner M,
KalckreuthW, Monaco AP. The chorea of McLeod
syndrome.Mov Disord. 2001;16(5):882-889. doi:10
.1002/mds.1188
49. Möller M, JöudM, Storry JR, OlssonML.
Erythrogene: a database for in-depth analysis of the
extensive variation in 36 blood group systems in
Clinical Review & Education Review Molecular Basis and Clinical Overview of McLeod Syndrome ComparedWith Other Neuroacanthocytosis Syndromes
E8 JAMANeurology Published online August 20, 2018 (Reprinted) jamaneurology.com
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 11/11/2018
the 1000 Genomes Project. Blood Adv. 2016;1(3):
240-249. doi:10.1182/bloodadvances.2016001867
50. International Society for Blood Transfusion Red
Cell Immunogenetics and Blood Group Terminology
Working Party. Names for Kx (ISBT 019) blood
group alleles. 2018. http://www.isbtweb.org
/fileadmin/user_upload/Working_parties/WP_on
_Red_Cell_Immunogenetics_and/019_XK_Alleles_v1.3
.pdf. Accessed December 19, 2017.
51. Ueyama H, Kumamoto T, Nagao S, et al. A novel
mutation of theMcLeod syndrome gene in a
Japanese family. J Neurol Sci. 2000;176(2):151-154.
doi:10.1016/S0022-510X(00)00307-5
52. Starling A, Schlesinger D, Kok F, Passos-Bueno
MR, Vainzof M, Zatz M. A family with McLeod
syndrome and calpainopathy with clinically
overlapping diseases.Neurology. 2005;65(11):
1832-1833. doi:10.1212/01.wnl.0000187073.58307.41
53. Dubielecka PM, Hwynn N, Sengun C, et al. Two
McLeod patients with novel mutations in XK.
J Neurol Sci. 2011;305(1-2):160-164. doi:10.1016/j
.jns.2011.02.028
54. Shimo H, Nakamura M, Tomiyasu A, Ichiba M,
Ueno S, Sano A. Comprehensive analysis of the
genes responsible for neuroacanthocytosis in mood
disorder and schizophrenia. Neurosci Res. 2011;69
(3):196-202. doi:10.1016/j.neures.2010.12.001
55. Klempír J, Roth J, Zárubová K, Písacka M,
Spacková N, Tilley L. TheMcLeod syndrome
without acanthocytes. Parkinsonism Relat Disord.
2008;14(4):364-366. doi:10.1016/j.parkreldis.2007
.07.011
56. Bansal I, Jeon HR, Hui SR, et al. Transfusion
support for a patient with McLeod phenotype
without chronic granulomatous disease and with
antibodies to Kx and Km. Vox Sang. 2008;94(3):
216-220. doi:10.1111/j.1423-0410.2007.01021.x
57. HoMF, Monaco AP, Blonden LAJ, et al. Fine
mapping of theMcLeod locus (XK) to a 150-380-kb
region in Xp21.Am JHumGenet. 1992;50(2):317-330.
58. Brown J, Dry KL, Edgar AJ, et al. Analysis of
three deletion breakpoints in Xp21.1 and the further
localization of RP3.Genomics. 1996;37(2):200-210.
doi:10.1006/geno.1996.0543
59. Arnaud L, Salachas F, Lucien N, et al.
Identification and characterization of a novel XK
splice site mutation in a patient with McLeod
syndrome. Transfusion. 2009;49(3):479-484. doi:
10.1111/j.1537-2995.2008.02003.x
60. Kang EM, Marciano BE, DeRavin S, Zarember
KA, Holland SM, Malech HL. Chronic granulomatous
disease: overview and hematopoietic stem cell
transplantation. J Allergy Clin Immunol. 2011;127(6):
1319-1326. doi:10.1016/j.jaci.2011.03.028
61. Hönig M, Flegel WA, Schwarz K, et al.
Successful hematopoietic stem-cell transplantation
in a patient with chronic granulomatous disease
andMcLeod phenotype sensitized to Kx and K
antigens. BoneMarrow Transplant.
2010;45(1):209-211. doi:10.1038/bmt.2009.115
62. Güngör T, Teira P, Slatter M, et al; Inborn Errors
Working Party of the European Society for Blood
andMarrow Transplantation. Reduced-intensity
conditioning and HLA-matched haemopoietic
stem-cell transplantation in patients with chronic
granulomatous disease: a prospective multicentre
study. Lancet. 2014;383(9915):436-448. doi:10
.1016/S0140-6736(13)62069-3
63. De Ravin SS, Li L, Wu X, et al. CRISPR-Cas9
gene repair of hematopoietic stem cells from
patients with X-linked chronic granulomatous
disease. Sci Transl Med. 2017;9(372):eaah3480. doi:
10.1126/scitranslmed.aah3480
64. Sürün D, Schwäble J, Tomasovic A, et al. High
efficiency gene correction in hematopoietic cells by
donor-template-free CRISPR/Cas9 genome editing.
Mol Ther Nucleic Acids. 2018;10:1-8. doi:10.1016/j
.omtn.2017.11.001
65. Dreyer AK, Hoffmann D, Lachmann N, et al.
TALEN-mediated functional correction of X-linked
chronic granulomatous disease in patient-derived
induced pluripotent stem cells. Biomaterials. 2015;
69:191-200. doi:10.1016/j.biomaterials.2015.07.057
66. De Franceschi L, Bosman GJ, Mohandas N.
Abnormal red cell features associated with
hereditary neurodegenerative disorders: the
neuroacanthocytosis syndromes. Curr Opin Hematol.
2014;21(3):201-209. doi:10.1097/MOH
.0000000000000035
Molecular Basis and Clinical Overview of McLeod Syndrome ComparedWith Other Neuroacanthocytosis Syndromes Review Clinical Review & Education
jamaneurology.com (Reprinted) JAMANeurology Published online August 20, 2018 E9
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 11/11/2018
